Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is an observational cohort study of virologic and immunologic outcome after at least 48 weeks of third line antiretroviral therapy. Upto 150 children at 8 Thai sites will be enrolled. Third line antiretroviral therapy in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will help the Thai government in planning its strategy to provide third line ARV therapy to children within the national program.
| Condition |
|---|
|
This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy. |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy |
- undetectable viral load [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]Primary endpoint will be the proportions of subjects with HIV RNA below 400 and 50 copies/ml at 48 weeks.
- Hyperlipidemia [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]Number of subjects with hyperlipidemia as a measure of safety
Biospecimen Retention: Samples Without DNA
Plasma and PBMC
| Estimated Enrollment: | 150 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
group 1
Children who are already on third line ARV or are switching to third line ARV may be enrolled in this observational study
|
Detailed Description:
The primary objective of this study is to assess the virological efficacy, as measured by the proportions of children with HIV RNA below 400 and 50 copies/ml at 48 weeks after initiating third line ARV therapy.
Third line ARV therapy is defined as an ARV regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Thai children aged < 18 years old who are on or are switching to third line antiretroviral therapy
Inclusion Criteria:
Children (< 18 years old) with HIV infection may enroll if one of the following criteria is met:
- Have resistance to at least one drug in each of the 3 classes (NRTI, NNRTI and PI) and have plasma HIV RNA > 1000 copies/ml prior to switching to third line ARV therapy
- Have intolerance to the current NRTI, NNRTI or PI treatment and need to receive darunavir, etravirine, tipranavir or raltegravir
Exclusion Criteria:
- Have hepatic impairment with ALT ≥ 5 upper limit of normal
- Pregnant or breastfeeding
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01225406
| Thailand | |
| Chulalongkorn University | |
| Bangkok, Thailand, 10330 | |
| HIV-NAT | |
| Bangkok, Thailand, 10330 | |
| Siriraj Hospital, Mahidol University | |
| Bangkok, Thailand, 10700 | |
| Prapokklao Chantaburi | |
| Chantaburi, Thailand, 22000 | |
| Nakornping Hospital | |
| Chiang Mai, Thailand, 50180 | |
| Chiang Rai Regional Hospital | |
| Chiang Rai, Thailand, 57000 | |
| Khon Kaen University | |
| Khon Kaen, Thailand, 40002 | |
| Bamrasnaradura Institute | |
| Nonthaburi, Thailand, 11000 | |
| Surin Hospital | |
| Surin, Thailand, 32000 | |
| Principal Investigator: | Thanyawee Puthanakit, MD | Chulalongkorn University, Bangkok | |
| Principal Investigator: | Kulkanya Chokephaibulkit, MD | Siriraj Hospital, Mahidol University, Bangkok, Thailand |
More Information
Additional Information:
No publications provided
| Responsible Party: | Jintanat Ananworanich, Associate Profeesor, The HIV Netherlands Australia Thailand Research Collaboration |
| ClinicalTrials.gov Identifier: | NCT01225406 History of Changes |
| Other Study ID Numbers: | HIV-NAT 113 |
| Study First Received: | October 18, 2010 |
| Last Updated: | February 7, 2013 |
| Health Authority: | Thailand: Ethical Committee |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
Third line ARV therapy HIV RNA Absolute CD4+ T cell count serious adverse events (SAEs) Drug resistance |
ClinicalTrials.gov processed this record on February 27, 2015